Abstract
Novartis has unveiled investments in China that are intended to help it capitalize on a population with increasing access to health care. The Swiss firm will sink $1 billion over the next five years into bolstering its R&D activities in China and will buy a majority stake in a Chinese vaccines company. Much of the R&D investment will go to the Novartis Institute for BioMedical Research in Shanghai (CNIBR). Focused on basic research into diseases that impact China, the institute will eventually house R&D in analytics and biomarkers, pharmacology, chemistry, proteomics and genomics, imaging, and protein production. The company expects to increase the number of associate-level scientists to roughly 1,000 from 160 today. To accommodate the added labs and manpower, CNIBR will move from Shanghai’s Zhangjiang Hi-Tech Park to a new campus in the city. Separately, Novartis signed a deal under which it will pay $125 million for an 85% stake in Zhenjiang Tianyuan Bio-Pharmaceutical, ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
